Stadlbauer, K.; Andorfer, P.; Stadlmayr, G.; Rüker, F.; Wozniak-Knopp, G.
Bispecific mAb2 Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab. Int. J. Mol. Sci. 2022, 23, 5208.
https://doi.org/10.3390/ijms23095208
AMA Style
Stadlbauer K, Andorfer P, Stadlmayr G, Rüker F, Wozniak-Knopp G.
Bispecific mAb2 Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab. International Journal of Molecular Sciences. 2022; 23(9):5208.
https://doi.org/10.3390/ijms23095208
Chicago/Turabian Style
Stadlbauer, Katharina, Peter Andorfer, Gerhard Stadlmayr, Florian Rüker, and Gordana Wozniak-Knopp.
2022. "Bispecific mAb2 Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab" International Journal of Molecular Sciences 23, no. 9: 5208.
https://doi.org/10.3390/ijms23095208
APA Style
Stadlbauer, K., Andorfer, P., Stadlmayr, G., Rüker, F., & Wozniak-Knopp, G.
(2022). Bispecific mAb2 Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab. International Journal of Molecular Sciences, 23(9), 5208.
https://doi.org/10.3390/ijms23095208